Forte Biosciences, Inc.
FBRX
$17.00
$1.338.49%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.97M | 2.84M | 3.18M | 2.96M | 3.43M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 22.44M | 24.57M | 18.38M | 11.58M | 16.12M |
| Operating Income | -22.44M | -24.57M | -18.38M | -11.58M | -16.12M |
| Income Before Tax | -21.76M | -23.75M | -17.68M | -11.25M | -15.66M |
| Income Tax Expenses | 373.00K | 1.04M | -- | -- | -- |
| Earnings from Continuing Operations | -22.14M | -24.79M | -17.68M | -11.25M | -15.66M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -22.14M | -24.79M | -17.68M | -11.25M | -15.66M |
| EBIT | -22.44M | -24.57M | -18.38M | -11.58M | -16.12M |
| EBITDA | -22.42M | -24.55M | -18.37M | -11.56M | -16.11M |
| EPS Basic | -1.24 | -1.39 | -0.99 | -0.96 | -1.37 |
| Normalized Basic EPS | -0.76 | -0.82 | -0.62 | -0.60 | -0.86 |
| EPS Diluted | -1.24 | -1.39 | -0.99 | -0.96 | -1.37 |
| Normalized Diluted EPS | -0.76 | -0.82 | -0.62 | -0.60 | -0.86 |
| Average Basic Shares Outstanding | 17.87M | 17.86M | 17.79M | 11.74M | 11.40M |
| Average Diluted Shares Outstanding | 17.87M | 17.86M | 17.79M | 11.74M | 11.40M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |